- Investing.com
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also develops surgical robot to enable placement of patient optimized orthopedic implants in the United States. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Strategic Expansion | Zimmer Biomet's acquisitions of Monogram Technologies and FNA aim to strengthen its position in orthopedic surgery and foot & ankle markets, signaling ambitious growth plans. |
Financial Health | With a "GREAT" financial score and consistent growth, Zimmer Biomet maintains operational stability. Analysts project 3-5% sales growth and $8.25 EPS for fiscal 2025. |
Innovation Pipeline | Explore Zimmer Biomet's focus on product innovation, including the OsseoFit Shoulder System and upcoming knee products, poised to drive future market share gains. |
Market Challenges | Delve into Zimmer Biomet's strategy to overcome U.S. Knees business weakness and tariff impacts, with price targets ranging from $101 to $140 per share. |
Metrics to compare | ZBH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZBHPeersSector | |
|---|---|---|---|---|
P/E Ratio | 27.1x | 22.7x | −0.5x | |
PEG Ratio | −1.36 | 0.16 | 0.00 | |
Price/Book | 1.5x | 2.8x | 2.6x | |
Price / LTM Sales | 2.3x | 2.0x | 3.3x | |
Upside (Analyst Target) | 3.7% | 42.1% | 47.0% | |
Fair Value Upside | Unlock | 33.6% | 6.1% | Unlock |